The potential for clinically significant drug-drug interactions in patients receiving CYP 2D6 model substrate/drugs and fluoxetine/paroxetine or sertraline.

被引：0
|
作者：
Preskorn, SH
Shah, R
Silkey, B
Neff, M
Golbeck, A
Choi, J
机构：
[1] Vet Affairs Med Ctr, Wichita, KS USA
[2] Inst Psychiat Res, Wichita, KS USA
[3] Vet Integrated Serv Network, Bay Pines, FL USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2004年 / 75卷 / 02期
关键词：
D O I：
10.1016/j.clpt.2003.11.266
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：P71 / P71
页数：1
相关论文
共 50 条
  • [21] Prediction of In Vivo Drug-Drug Interactions from In Vitro DataFactors Affecting Prototypic Drug-Drug Interactions Involving CYP2C9, CYP2D6 and CYP3A4
    Hayley S. Brown
    Aleksandra Galetin
    David Hallifax
    J. Brian Houston
    Clinical Pharmacokinetics, 2006, 45 : 1035 - 1050
  • [22] PBPK modeling to predict the pharmacokinetics of venlafaxine and its active metabolite in different CYP2D6 genotypes and drug-drug interactions with clarithromycin and paroxetine
    Cho, Chang-Keun
    Kang, Pureum
    Jang, Choon-Gon
    Lee, Seok-Yong
    Lee, Yun Jeong
    Bae, Jung-Woo
    Choi, Chang-Ik
    ARCHIVES OF PHARMACAL RESEARCH, 2024, 47 (05) : 481 - 504
  • [23] Prediction of in vivo drug-drug interactions from in vitro data -: Factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4
    Brown, Hayley S.
    Galetin, Aleksandra
    Hallifax, David
    Houston, J. Brian
    CLINICAL PHARMACOKINETICS, 2006, 45 (10) : 1035 - 1050
  • [24] Potential Drug-Drug Interactions in Oncology Patients Receiving Anti-Cancer Drugs in a Tertiary Medical Centre in Taiwan
    Ho, Chin-Chin
    Yang, Chen-Chang
    Chou, Yueh-Ching
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 : 279 - 280
  • [25] Desipramine, substrate for CYP2D6 activity: population pharmacokinetic model and design elements of drug-drug interaction trials
    Gueorguieva, Ivelina
    Jackson, Kimberley
    Wrighton, Steven A.
    Sinha, Vikram P.
    Chien, Jenny Y.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 70 (04) : 523 - 536
  • [26] Physiologically Based Pharmacokinetic Model of the CYP2D6 Probe Atomoxetine: Extrapolation to Special Populations and Drug-Drug Interactions
    Huang, Weize
    Nakano, Mariko
    Sager, Jennifer
    Ragueneau-Majlessi, Isabelle
    Isoherranen, Nina
    DRUG METABOLISM AND DISPOSITION, 2017, 45 (11) : 1156 - 1165
  • [27] A general model for quantitative prediction of drug exposure in case of drug-drug interactions on polymorphic cytochroms 2D6, 2C9 and 2C19
    Tod, M.
    Goutelle, S.
    Castellan, C.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2013, 27 : 20 - 20
  • [28] Physiologically-Based Pharmacokinetic Models of CYP2D6 Substrate and Inhibitors Nebivolol, Cinacalcet and Mirabegron to Simulate Drug-Drug Interactions
    Kilford, Peter
    Khoshaein, Nika
    Southall, Roz
    Gardner, Iain
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2022, 47 (05) : 699 - 710
  • [29] Potential drug-drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments
    Lemaitre, Florian
    Solas, Caroline
    Gregoire, Matthieu
    Lagarce, Laurence
    Elens, Laure
    Polard, Elisabeth
    Saint-Salvi, Beatrice
    Sommet, Agnes
    Tod, Michel
    Guellec, Chantal Barin-Le
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2020, 34 (05) : 530 - 547
  • [30] Fluoxetine- and Norfluoxetine-Mediated Complex Drug-Drug Interactions: In Vitro to In Vivo Correlation of Effects on CYP2D6, CYP2C19, and CYP3A4
    Sager, J. E.
    Lutz, J. D.
    Foti, R. S.
    Davis, C.
    Kunze, K. L.
    Isoherranen, N.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 (06) : 653 - 662
12345